Dysmenorrhea in Combination with Endometriosis in Adolescence and Early Reproductive Age

О.Л. Иванишкина-Кудина
In: Репродуктивное здоровье. Восточная Европа · 2022 · pp. 288–294 · doi:10.34883/pi.2022.12.2.012 · W4281732458
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This paper reports the high prevalence of dysmenorrhea in young women and adolescents, advocating for timely diagnosis and progesterone therapy to optimize treatment efficiency and minimize side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Распространенность дисменореи среди женщин молодого возраста и подростков крайне высока. Своевременная диагностика первичной и вторичной форм дисменореи в молодом возрасте позволяет выбрать обоснованную патогенетическую терапию прогестероном, которая даст возможность совместить высокую эффективность с одновременным снижением нежелательных медикаментозных и гормональных нагрузок при длительной терапии заболевания. The prevalence of dysmenorrhea among young women and adolescents is extremely high. Diagnosis of primary and secondary forms of dysmenorrhea at a young age makes it possible to choose a reasonable pathogenetic progesterone therapy, which will combine high efficiency and at the same time reduce unwanted drug and hormonal during long-term therapy of the disease.

My notes (saved in your browser only)

Condition tags

endometriosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK